Form 8-K - Current report:
SEC Accession No. 0001664710-24-000072
Filing Date
2024-08-28
Accepted
2024-08-28 08:01:26
Documents
14
Period of Report
2024-08-28
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K kros-20240828.htm   iXBRL 8-K 37953
2 EX-99.1 exhibit99182824pr.htm EX-99.1 11743
  Complete submission text file 0001664710-24-000072.txt   179228

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT kros-20240828.xsd EX-101.SCH 1901
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT kros-20240828_lab.xml EX-101.LAB 22548
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT kros-20240828_pre.xml EX-101.PRE 13046
16 EXTRACTED XBRL INSTANCE DOCUMENT kros-20240828_htm.xml XML 2823
Mailing Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421
Business Address 1050 WALTHAM STREET, SUITE 302 LEXINGTON MA 02421 617-314-6297
Keros Therapeutics, Inc. (Filer) CIK: 0001664710 (see all company filings)

EIN.: 811173868 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39264 | Film No.: 241251101
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)